与IVC相结合的TAPSE/PASP可以识别低风险和中等风险的PAH患者的不良预后
Wei Qian1,2, Yue Zhang1,2, Jiayi Dai1,2
1The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu Province, China.
Clinical rheumatology
|December 26, 2025
概括
结合TAPSE/PASP比率和IVC直径的简单回声心脏仪器可以预测肺动脉高血压 (PAH) 患者的不良预后. 这种方法有助于早期风险分层,以便在低风险和中等风险的PAH中更好地调整治疗.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 医疗成像医学成像
背景情况:
- 肺动脉高血压 (PAH) 需要准确的预后评估才能有效管理.
- 低风险和中等风险PAH患者的风险分层对于及时干预至关重要.
- 心声图提供了评估心脏功能和预后的非侵入性参数.
研究的目的:
- 为了确定回声心脏学参数,预测低风险和中等风险PAH患者的预后.
- 评估TAPSE/PASP比率和IVC直径对风险分层的联合实用性.
- 提供一个简单的工具,用于早期识别PAH的不良预后.
主要方法:
- 对116名被归类为低风险或中等风险的PAH患者进行了回顾性队列研究.
- 收集的数据包括基线和随访心声学和临床参数.
- 统计分析涉及对缺少数据的随机森林归算和生存分析.
主要成果:
- TAPSE/PASP比率是预后不佳的独立预测因素 (p=0.015).
- 在TAPSE/PASP<0.33和IVC≥16mm的患者中,无事件生存率显著降低 (p<0.001).
- 这种组合在24.1%的经历临床失败事件的患者中发现了不良预后.
结论:
- TAPSE/PASP<0.33和IVC≥16毫米的组合有效地识别了低风险和中等风险PAH的不良预后.
- 这种简单的回声心脏指数有助于早期风险分层和识别右心室肺动脉脱.
- 这些发现支持个性化的长期管理,通过改进传统标准之外的风险评估来支持个性化的长期管理.
相关概念视频
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
413
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
413
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
435
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
435